.jpg "Anti-ZAP70 Specificity Assay (Array)")
.jpg "ZAP70 IHC human Tonsil (ZAP70 2035)")
.jpg "SDS-PAGE Anti-ZAP70(ZAP70 2035)")
PDF DatasheetHuman Anti-ZAP70 (Chronic Lymphocytic Leukemia Marker) Antibody Product Attributes
ZAP70 (Chronic Lymphocytic Leukemia Marker) Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Variations in ZAP70 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in lymphoid tissue in appendix and non-germinal center cells in the lymph node and tonsil. More moderate antibody staining intensity was present in lymphoid tissue in appendix and non-germinal center cells in the lymph node and tonsil. Low, but measureable presence of ZAP70 could be seen inmacrophages in lung and cells in the white pulp in spleen. We were unable to detect ZAP70 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Type:
Tissues from cancer patients, for instance, have their own distinct pattern of ZAP70 expression as measured by anti-ZAP70 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | + | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| ZAP70 Variability | ++ | + | + | + | + | + | + | + | + | ++ | + | + | + | + | + | ++ | ++ | + | + | + |
| ZAP70 (Chronic Lymphocytic Leukemia Marker) General Information | |
|---|---|
| Alternate Names | |
| Selective T cell defect; SRK; STD; Syk-related tyrosine kinase; Tyrosine-protein kinase ZAP-70;TZK; Zeta chain associated protein kinase 70kDa | |
| Molecular Weight | |
| 70kDa | |
| Chromosomal Location | |
| Ships on blue ice. | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | 7535 |
| Entrez Gene ID | ZAP70 |
| UniProt ID(s) | P43403 |
| UniGene ID(s) | Hs234569 |
| COSMIC ID Link(s) | ZAP70 |
| KEGG Gene ID(s) | hsa:7535 |
| General Description of ZAP70 (Chronic Lymphocytic Leukemia Marker). | |
| ZAP70 is a 70kDa protein tyrosine kinase found in T-cells and natural killer cells. Control of this protein translation is via the IgVH gene. ZAP70 protein is expressed in leukemic cells of approximately 25% of chronic lymphocytic leukemia (CLL) cases as well. Anti-ZAP70 expression is an excellent surrogate marker for the distinction between the Ig-mutated (anti-ZAP70 negative) and Ig-unmutated (anti-ZAP70 positive) CLL subtypes and can identify patient groups with divergent clinical courses. The anti-ZAP70 positive Ig-unmutated CLL cases have been shown to have a poorer prognosis. | |
There are no reviews yet.